80121-65-9

Basic information

• Product Name: 1,3-Bis(2-hydroxyethyl)adamantane
• Synonyms: 1,3-Bis(2-hydroxyethyl)adamantane;Tricyclo[3.3.1.13,7]decane-1,3-diethanol;3-Bis(2-hydroxyethyl)adaMantane;2,2-(Adamantane-1,3-diyl)diethanol
• CAS NO: 80121-65-9
• Molecular Formula: C₁₄H₂₄O₂
• Molecular Weight: 224.3392
• Mol File: 80121-65-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 117-118℃
• Boiling Point: 351.2 °C at 760 mmHg
• Flash Point: 163.6 °C
• Appearance: /
• Density: 1.126
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,3-Bis(2-hydroxyethyl)adamantane(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Bis(2-hydroxyethyl)adamantane(80121-65-9)
• EPA Substance Registry System: 1,3-Bis(2-hydroxyethyl)adamantane(80121-65-9)

Safety Data

• Hazardous Substances Data: 80121-65-9(Hazardous Substances Data)

Usage

General Description

1,3-Bis(2-hydroxyethyl)adamantane, also known as BHEA, is a chemical compound with a unique molecular structure. It is a derivative of adamantane, a diamondoid hydrocarbon, and contains two hydroxyethyl groups attached to carbon atoms 1 and 3 of the adamantane backbone. BHEA is used in the synthesis of polymers and as a building block for the creation of novel materials. It has been studied for its potential use in drug delivery systems, as well as in the development of new types of surfactants and lubricants. Additionally, BHEA has been investigated for its potential antioxidant and antimicrobial properties. Overall, 1,3-Bis(2-hydroxyethyl)adamantane is a versatile compound with a range of potential applications in various fields of science and technology.

Upstream product

• 17768-28-4 1,3-adamantane diacetic acid 
• 81657-07-0 (3-ethoxycarbonylmethyl-adamantan-1-yl)-acetic acid ethyl ester 
• 17768-29-5 dimethyl adamantane-1,3-diyldiacetate 

Downstream Products

• 2082-81-7 butane-1,4-diyl di(methacrylate) 
• 80121-66-0 1,3-bis[(2-tosyloxyethyloxy)methyl]adamantane 

Relevant articles and documents

Four-Directional synthesis of adamantane derivatives

1-Adamantanemethanol, 1,3-adamantanedimethanol and 1,3,5,7-adamantanetetramethanol were converted into adamantanes functionalized with one or four (2R,1S)-2-formyl-1-cyclopropyl residues using Charette enantioselective cyclopropanation reactions and with one, two or four 4-ethoxy- (or 4-t-butoxy)-3-diazo-2,4- dioxobutyl residues from aldehyde and diazo-acetate ester condensation reactions by 1-directional, 2- directional or 4-directional syntheses. The synthesis of adamantane fused to cyclopentadiene is also reported. 'Equation Presented'.

Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof

The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.

AMANTADINE NITRATE COMPOUND HAVING A NEUROPROTECTIVE EFFECT AND PREPARATION AND MEDICAL USE THEREOF

The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.